C
Chandra P. Belani
Researcher at Penn State Cancer Institute
Publications - 490
Citations - 28781
Chandra P. Belani is an academic researcher from Penn State Cancer Institute. The author has contributed to research in topics: Lung cancer & Carboplatin. The author has an hindex of 67, co-authored 481 publications receiving 26986 citations. Previous affiliations of Chandra P. Belani include Emory University & University of Maryland Marlene and Stewart Greenebaum Cancer Center.
Papers
More filters
Journal ArticleDOI
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Joan H. Schiller,David P. Harrington,Chandra P. Belani,Corey J. Langer,Alan B. Sandler,James E. Krook,Junming Zhu,David H. Johnson +7 more
TL;DR: None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non-small-cell lung cancer.
Journal ArticleDOI
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial
Mark G. Kris,Ronald B. Natale,Roy S. Herbst,Thomas J. Lynch,Diane Prager,Chandra P. Belani,Joan H. Schiller,Karen Kelly,Harris Spiridonidis,Alan B. Sandler,Kathy S. Albain,David Cella,Michael K. Wolf,Steven D. Averbuch,Judith Ochs,Andrea C. Kay +15 more
TL;DR: Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer
Mark G. Kris,Ronald B. Natale,Roy S. Herbst,Diane Prager,Chandra P. Belani,Joan H. Schiller,Karen Kelly,Harris Spiridonidis,Alan B. Sandler,Kathy S. Albain,David Cella,Michael K. Wolf,Steven D. Averbuch,Judith Ochs,Andrea C. Kay +14 more
TL;DR: Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy as mentioned in this paper.
Journal ArticleDOI
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Tudor Ciuleanu,Thomas Brodowicz,Christoph C. Zielinski,Joo Hang Kim,Maciej Krzakowski,E. Laack,Yi-Long Wu,Isabel Bover,Stephen Begbie,Valentina Tzekova,Branka Cucevic,José Rodrigues Pereira,Sung Hyun Yang,Jayaprakash Madhavan,Katherine P. Sugarman,Patrick Peterson,William J. John,K. Krejcy,Chandra P. Belani +18 more
TL;DR: Maintenance therapy with pemetrexed is well tolerated and offers improved progression-free and overall survival compared with placebo in patients with advanced non-small-cell lung cancer.
Journal ArticleDOI
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
Frank V. Fossella,José Rodrigues Pereira,Joachim von Pawel,Anna Pluzanska,Vera Gorbounova,E. Kaukel,K. Mattson,Rodryg Ramlau,Aleksandra Szczesna,Panagiotis Fidias,Michael Millward,Chandra P. Belani +11 more
TL;DR: DC resulted in a more favorable overall response and survival rate than VC, demonstrating that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.